CVS Health’s insurance and health services units outperformed Wall Street in the third quarter, yet the bigger story for investors was the company’s breakup plan.
The federal government in September 2024 sued the country’s three largest pharmacy benefit managers for allegedly inflating the list price of insulin drugs.
